Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the do ut des paradigm)
作者： Gilberto de Castro Junior , Fabio Puglisi , Evandro de Azambuja , Nagi S. El Saghir , Ahmad Awada
DOI: 10.1016/J.CRITREVONC.2006.02.007
关键词:
摘要: Angiogenesis plays a crucial role in facilitating tumor growth and the metastatic process, it is result of dynamic balance between pro-angiogenic factors, like vascular endothelial factor (VEGF) platelet-derived factor, antiangiogenic thrombospondin-1 angiostatin. Many drugs that target human tumors, bevacizumab some VEGF-receptor tyrosine-kinase inhibitors (e.g., BAY 43-9006, SU11248 PTK787/ZK222584) have been studied clinical trials, with favorable toxicity reports encouraging results advanced colorectal cancer, renal cell breast cancer non-squamous non-small lung either combined chemotherapy, or monotherapy. Another potential approach to inhibiting angiogenesis through metronomic chemotherapy (low doses for long periods time). This review describes mechanisms angiogenic process evaluates recent data about therapies trials.
ulb.ac.be
elsevier.com
croh-online.com 
core.ac.uk 参考文章(94)
Sarah Kimmina, Valentin Goede, Hellmut G. Augustin, Detlef Kozian, Tobias Schmidt, Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Laboratory Investigation. ,vol. 78, pp. 1385- 1394 ,(1998)
Giampietro Gasparini, Adrian L. Harris, Prognostic Significance of Tumor Vascularity Humana Press, Totowa, NJ. pp. 317- 339 ,(1999) , 10.1007/978-1-59259-453-5_18
Timothy Browder, Jan Palmblad, Judah Folkman, Angiogenesis research: guidelines for translation to clinical application. Thrombosis and Haemostasis. ,vol. 86, pp. 23- 33 ,(2001) , 10.1055/S-0037-1616197
Antiangiogenic agents in cancer therapy Humana Press,. ,(1998) , 10.1007/978-1-59259-453-5
Robert S. Kerbel, A cancer therapy resistant to resistance Nature. ,vol. 390, pp. 335- 336 ,(1997) , 10.1038/36978
Rakesh K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine. ,vol. 7, pp. 987- 989 ,(2001) , 10.1038/NM0901-987
Susan LeJeune, Russell Leek, Stephen Fox, Ruth Whitehouse, Amir Moghaddam, Prudence A. E. Scott, Roy Bicknell, Micheie Relf, Kenneth Smith, Adrian L. Harris, Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Research. ,vol. 57, pp. 963- 969 ,(1997)
Patrick H. Maxwell, Michael S. Wiesener, Gin-Wen Chang, Steven C. Clifford, Emma C. Vaux, Matthew E. Cockman, Charles C. Wykoff, Christopher W. Pugh, Eamonn R. Maher, Peter J. Ratcliffe, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature. ,vol. 399, pp. 271- 275 ,(1999) , 10.1038/20459
HX Chen, M Mooney, M Boron, L Grochow, J Zwiebel, D Vena, K Mosby, C Grandinetti, RS Kaplan, None, Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301) Journal of Clinical Oncology. ,vol. 22, pp. 3515- 3515 ,(2004) , 10.1200/JCO.2004.22.90140.3515
Dieter Marmé, Karin Weindel, Georg Martiny-Baron, Bernhard Barleon, Katja Mohrs, Gerhard Siemeister, Reversion of Deregulated Expression of Vascular Endothelial Growth Factor in Human Renal Carcinoma Cells by von Hippel-Lindau Tumor Suppressor Protein Cancer Research. ,vol. 56, pp. 2299- 2301 ,(1996)